We demonstrate circulatory compensation of anaemia by enhanced eNOS expression in the arterial wall and increased NO bioactivity as reflected by enhanced FMD, which was abrogated with pharmacological or genetic disruption of eNOS activity, and by the attenuation of the anaemia-induced drop of MAP by L-NAME. The gene discussed is NOS3; the disease is anemia (phenotype).